2018
General Thoracic Surgery in Rwanda: An Assessment of Surgical Volume and of Workforce and Material Resource Deficits
Ramirez A, Nuradin N, Byiringiro F, Ntakiyiruta G, Giles A, Riviello R. General Thoracic Surgery in Rwanda: An Assessment of Surgical Volume and of Workforce and Material Resource Deficits. World Journal Of Surgery 2018, 43: 36-43. PMID: 30132227, PMCID: PMC6318006, DOI: 10.1007/s00268-018-4771-y.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAnesthesiologyChildChild, PreschoolEquipment and Supplies, HospitalFemaleHealth WorkforceHospitals, PrivateHospitals, UniversityHumansInfantInfant, NewbornMaleMiddle AgedNeeds AssessmentRetrospective StudiesRwandaSimulation TrainingThoracic SurgeryThoracic Surgical ProceduresYoung AdultConceptsUniversity Teaching HospitalHuman Resources for Health (HRH) ProgramThoracic casesSurgical volumeSimulation trainingUniversity Teaching Hospital of KigaliUniversity Teaching Hospital of ButareWorld Health Organization formBaseline patient characteristicsOperative volumeRetrospective cohort studyGeneral surgery proceduresThoracic surgical careGeneral thoracic surgeryOperating room registriesHRH ProgramPearson chi-square testKing Faisal HospitalAddress barriersCapacity building programsChi-square testKruskal-Wallis testNeeds assessmentPatient accessReferral center
2015
Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials’ experience
Ramirez A, Wages N, Hu Y, Smolkin M, Slingluff C. Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials’ experience. Cancer Immunology, Immunotherapy 2015, 64: 1531-1539. PMID: 26392296, PMCID: PMC4644444, DOI: 10.1007/s00262-015-1758-5.Peer-Reviewed Original ResearchConceptsDisease-free survivalT cell responsesOverall survivalImmune responseOlder patientsCancer vaccinesClinical outcomesResected stage IIB-IV melanomaCD8+ T cell responsesStage IIB-IV melanomaLonger disease-free survivalImpact of patient ageMelanoma-associated peptidesCancer vaccine trialsClinical trial experienceIncidence of IRCumulative incidence rateKaplan-Meier estimatesClass I MHCMelanoma vaccineMenopausal statusPatient ageSurvival outcomesStratify patientsFemale patients